Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SABRATEK CORP (SBTK) -- Ignore unavailable to you. Want to Upgrade?

To: Pluvia who wrote (163)	6/17/1999 12:30:00 PM
From: mod	Read Replies (2) \| Respond to of 487

So far, you haven't scared off any analysts yet. Of course, you don't care what analysts say, you use Milberg Weiss as your broker, right? ps: I will admit, I never heard of these guys, and would not rely on them for investment decisions, but I just wanted to show that I can cut and paste just like you can. Roney & Co. One Griswold Street · Detroit, MI 48226 DAILY RESEARCH NOTES June 16, 1999 Sabratek Corp. (SBTK-$20 1/4:NASDAQ) Lynn D. Malkes June 16, 1999 EPS Estimates 1998A 1999E 2000E Rating: Buy $0.44 $0.70 $1.15 Down as quickly as it went up. A downdraft in the shares of Sabratek yesterday was caused by the law firm of Milberg Weiss, which is well known for its class action lawsuits against publicly traded companies. The law firm' s current suit against Sabratek, filed in January of this year on behalf of investors who purchased common shares between January 13, 1998 to November 24, 1998 was recently amended to include allegations of accounting irregularities. Instead of detailing the allegations, which we believe do not have any merit, we emphasize the very positive fundamentals of Sabratek and its cutting edge strategy of combining information technology with patient care. We like this story a lot and continue to recommend purchase for aggressive growth investors— our 12-month target is $32. Skokie, Illinois-based Sabratek develops, produces and markets technologically-advanced, user-friendly and cost-effective therapeutic and diagnostic medical systems designed specifically to meet the unique needs of the alternate-site health care market. The company' s multi-therapy infusion and other devices and data management systems incorporate advanced communications technology. Sabratek' s founding vision and strategic focus is the creation of a virtual hospital room for the alternate-site health care market. The alternative care site market includes long-term care facilities, doctors' offices, outpatient centers, home care and is estimated to be approximately $22 billion in size, growing at a rate just over 20% annually. Advances in medical care have reduced the mortality rates of catastrophic illnesses (e.g., stroke, heart failure), although survivors may experience significant disability and recurrent complications that require sophisticated care. Improvements in medical technology now permit complex monitoring and care to be administered outside hospitals. Patients and physicians are becoming more comfortable receiving and providing medical care in nonacute settings. Sabratek' s products include multi-therapy infusion pumps, which are attached to a phone line, allowing a nurse or physician to monitor the therapy and alter doses as needed from a remote location. Also in the company' s product portfolio are vital signs monitors that transmit patient care data such as blood pressure, heartbeat, glucose levels, oxygen, etc. from a person' s home or other care site to caregivers in other locations.

To: Pluvia who wrote (163)	6/17/1999 12:30:00 PM
From: Swanny	Respond to of 487

You tell me, Steve. Whose lead should I follow in a company that has a huge short position dramatically higher than the float. That of a known shill of the shorts or that of Charles Stewart, who recently bought a couple hundred thousand shares at prices as high as 28 5/8 and increased his stake in the company to 5.84%. Which one probably knows what is going on at the company? Which one has friends who will be totally screwed if more very positive news comes out? I imagine if Mr. Stewart was buying at 28 5/8, he would enjoy buying more at 22-23.